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ABSTRACT Theuseofpneumococcalcapsularpolysaccharide(PPS)-basedvaccineshasresultedinasubstantialreductioninin-
vasivepneumococcaldisease.However,muchremainstobelearnedaboutvaccine-mediatedimmunity,asseven-valentPPS-
proteinconjugatevaccineuseinchildrenhasbeenassociatedwithnonvaccineserotypereplacementand23-valentvaccineusein
adultshasnotpreventedpneumococcalpneumonia.Inthisreport,wedemonstratethatcertainPPS-speciﬁcmonoclonalanti-
bodies (MAbs) enhance the transformation frequency of two different Streptococcus pneumoniae serotypes. This phenomenon
wasmediatedbyPPS-speciﬁcMAbsthatagglutinatebutdonotpromoteopsoniceffectorcellkillingofthehomologousserotype
in vitro. Compared to the autoinducer, competence-stimulating peptide (CSP) alone, transcriptional proﬁling of pneumococcal
geneexpressionafterincubationwithCSPandonesuchMAbtothePPSofserotype3revealedchangesintheexpressionofcom-
petence(com)-relatedandbacteriocin-likepeptide(blp)genesinvolvedinpneumococcalquorumsensing.ThisMAbwasalso
foundtoinduceanearly2-foldincreaseinCSP2-mediatedbacterialkillingorfratricide.Theseobservationsrevealanovel,direct
effectofPPS-bindingMAbsonpneumococcalbiologythathasimportantimplicationsforantibodyimmunitytopneumococcus
inthepneumococcalvaccineera.Takentogether,ourdatasuggestheretoforeunsuspectedmechanismsbywhichPPS-speciﬁc
antibodiescouldaffectgeneticexchangeandbacterialviabilityintheabsenceofhostcells.
IMPORTANCE Currentthoughtholdsthatpneumococcalcapsularpolysaccharide(PPS)-bindingantibodiesprotectagainstpneu-
mococcusbyinducingeffectorcellopsonickillingofthehomologousserotype.Whilesuchantibodiesareanimportantpartof
howpneumococcalvaccinesprotectagainstpneumococcaldisease,PPS-speciﬁcantibodiesthatdonotexhibitthisactivitybut
arehighlyprotectiveagainstpneumococcusinmicehavebeenidentiﬁed.ThisarticleexaminestheeffectofnonopsonicPPS-
speciﬁc monoclonal antibodies (MAbs) on the biology of Streptococcus pneumoniae. The results showed that in the presence of a
competence-stimulatingpeptide(CSP),suchMAbsincreasethefrequencyofpneumococcaltransformation.Furtherstudies
withonesuchMAbshowedthatitalteredtheexpressionofgenesinvolvedinquorumsensingandincreasedcompetence-
inducedkillingorfratricide.Theseﬁndingsrevealanovel,previouslyunsuspectedmechanismbywhichcertainPPS-speciﬁc
antibodiesexertadirecteffectonpneumococcalbiologythathasbroadimplicationsforbacterialclearance,geneticexchange,
andantibodyimmunitytopneumococcus.
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T
he introduction of the seven-valent pneumococcal conjugate
vaccine(PCV7)in2000ledtoaremarkabledeclineininvasive
pneumococcaldiseasecausedbyvaccine-includedserotypes(STs)
(1). Despite this resounding success, the battle against pneumo-
coccal disease continues to present a formidable challenge in two
main areas, namely, that PCV7 use has been associated with ST
replacement(2)andtheefﬁcacyofthe23-valentPPSvaccinedoes
not extend to the prevention of pneumonia (3, 4). PCV coverage
has now been expanded to 13 STs (PCV13), and next-generation
pneumococcal vaccines that promise to provide universal (non-
ST-speciﬁc) coverage are under consideration (5). Nonetheless,
the aforementioned challenges underscore the fact that there is
more to learn about vaccine-mediated protection against pneu-
mococcal disease.
PPS-basedvaccinesmediateprotectionagainstpneumococcus
by inducing PPS-speciﬁc antibodies. Given that the Gram-
positive cell wall precludes antibody and complement opsonins
from exerting a direct effect on pneumococcal viability, the pri-
mary mechanism by which such antibodies mediate protection is
considered to be that they promote opsonic killing of the homol-
ogousSTbyhostphagocytes(6).ST-speciﬁc,antibody-dependent
enhancement of phagocyte-mediated (opsonophagocytic) killing
ofthehomologousSTinvitrohasemergedasthegoldstandardfor
the assessment of PCV immunogenicity (7). Nonetheless, human
and mouse PPS-speciﬁc monoclonal antibodies (MAbs) that are
highly protective against pneumococcal pneumonia and sepsis in
mouse models but do not promote opsonic killing in vitro have
been identiﬁed (8–10). Although the mechanism by which such
RESEARCH ARTICLE
September/October 2011 Volume 2 Issue 5 e00176-11
® mbio.asm.org 1MAbsinducebacterialclearanceremainsunderinvestigation,the
efﬁcacyofonenonopsonicMAbwasshowntodependonitsabil-
ity to induce bacterial agglutination (8, 11). Agglutination can
enhance cell-cell communication and is a characteristic of pneu-
mococcus in its competent state (12). Given that competence is
regulated by quorum sensing and certain quorum-sensing mole-
cules have been shown to have immunomodulatory and protec-
tive activity in bacterial infection models (13, 14), we investigated
the effect of PPS-speciﬁc MAbs on pneumococcal quorum sens-
ing. Our data show that certain non-opsonic MAbs increase the
frequency of pneumococcal transformation. Further studies with
one such MAb showed that it induces a second wave of quorum
sensing,anincreaseinfratricide,andchangesincompetence-and
fratricide-related gene expression compared to competence-
stimulatingpeptide(CSP)alone.Theseﬁndingsdemonstratethat
certain PPS-speciﬁc antibodies can exert a direct effect on pneu-
mococcal biology and viability.
(Some of the data in this article are from a thesis submitted by
Masahide Yano in partial fulﬁllment of the requirements for the
degree of Doctor of Philosophy in the Sue Golding Graduate Di-
vision of Medical Science, Albert Einstein College of Medicine,
Yeshiva University, Bronx, NY.)
RESULTS
Protective PPS-speciﬁc MAbs increase the frequency of pneu-
mococcal transformation and induce bacterial agglutination.
The transformation frequencies of Streptococcus pneumoniae ST3
(A66.1)andST8(6308)strainsweredeterminedinthepresenceof
pneumococcal CSP with and without PPS-speciﬁc and isotype
control MAbs. The effect of MAb 1E2, a PPS3-speciﬁc mouse
IgG1() that protects against ST3 pneumonia and bacteremia in
micebutdoesnotpromoteopsonickillingofST3invitro(9),was
investigated by adding it to ST3 (A66.1) or a clinical ST3 strain,
LI-736(15),inthepresenceofCSP2.Additionof1E2resultedina
higher frequency of transformation of A66.1 and the multidrug-
resistant (MDR) clinical strain signiﬁcantly than that observed
with CSP2 alone (no MAb) or control MAbs with CSP2 (Fig. 1a).
A MAb-induced increase in transformation frequency compared
FIG 1 MAbs 1E2 and A7 increase the transformation frequency of ST3 pneumococcal cells. (a) 1E2 (nonopsonic mouse IgG1 to PPS3) increases the
CSP2-mediatedtransformationfrequencyofST3(A66.1)pneumococcalcells,incontrasttoopsonicST3MAb5F6(mouseIgG1toPPS3)(P0.05byone-way
ANOVA,P0.05byTukey’smultiple-comparisontest)andisotype-matchedcontrolMAb31B12(P0.05byTukey’smultiple-comparisontest).HumanIgM
MAb A7 (IgM to PPS3) also led to a statistically signiﬁcant increase in the frequency of transformation, in contrast to control MAb (CT antibody [Ab]) G19 (P
 0.05 by Tukey’s multiple-comparison test). G19 (human IgM) binds to C. neoformans capsular polysaccharide and was used as a matched isotype-matched
control.(b)1E2increasesthetransformationfrequencyofanMDRST3clinicalstrain(LI-736),incontrastto31B12(opsonicmouseIgG1toPPS8;P0.05by
one-way ANOVA, P  0.05 by Tukey’s multiple-comparison test) and 5F6 (mouse IgG1 to PPS3; P  0.05 by Tukey’s multiple-comparison test). (c) 1E2
enhances the transformation frequency of A66.1 in a dose-dependent manner (P  0.05 by two-way ANOVA, P  0.050 comparing untreated versus 1 g and
1 g versus 10 g by Tukey’s multiple-comparison test). Experiments were performed as described in Materials and Methods (see supplemental material). (d)
Two IgM MAbs, 54B11 (human IgM to PPS8) and 28H11 (nonopsonic mouse IgM to PPS8), increase the CSP1-mediated transformation frequency of ST8
pneumococcal cells (6308), in contrast to the isotype- and species-matched control MAb (P  0.05 by one-way ANOVA, P  0.05 by Tukey’s multiple-
comparison test). 31B12 (opsonic mouse IgG1 to PPS8) does not change the transformation frequency of 6308 cells. Wt, wild type.
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human PPS3-speciﬁc IgM MAb that is protective against ST3 in
mice(11),butnotwith5F6,anopsonicmousePPS3-speciﬁcIgG1
that is protective in mice (9); 31B12, a nonopsonic, mouse PPS8-
speciﬁc IgG1 MAb (see Fig. S1 in the supplemental material) that
is protective against another ST (ST8) in mice (16); or an isotype-
matched control MAb (Fig. 1a). The 1E2-induced increase in
transformation frequency of the MDR ST3 isolate was larger than
thatofA66.1(Fig.1b).Theeffectof1E2(mouseIgG1toPPS3)on
CSP2-mediatedtransformationexhibitedadose-dependenttrend
thatwasstatisticallysigniﬁcantcomparedtothatobtainedwithno
MAb (Fig. 1c).
Experiments with the ST8 strain (6308) were performed
with54B11,ahumanIgMPPS8-speciﬁcMAbthatisprotective
inmice(unpublisheddata);28H11,amouseIgMPPS8-speciﬁc
MAb that is protective in mice (16) and nonopsonic in vitro
(see Fig. S1 in the supplemental material); 31B12, a mouse
IgG1 PPS8-speciﬁc MAb that induces opsonic killing of ST8 in
vitro (see Fig. S1 in the supplemental material); and 5G6, an
MAb to another pneumococcal determinant, phosphorylcho-
line (PC), that is not protective in mice (16). MAbs 54B11
(human IgM to PPS8) and 28H11 (mouse IgM to PPS8) each
increasedthetransformationfrequencyof6308morethanCSP
alone, but 31B12 (mouse IgG1 to PPS8) and an isotype-
matched control did not (Fig. 1d).
To investigate the association between MAb-mediated in-
creases in transformation frequency and bacterial agglutination,
we mixed 10 g PPS-speciﬁc MAb with 106 ﬂuorescently labeled
CFU of the homologous ST and examined the reaction product
for agglutination by ﬂuorescence microscopy. A7 (nonopsonic
human IgM to PPS3), 1E2 (nonopsonic mouse IgG1 to PPS3)
(Fig. 2a), 54B11 (human IgM to PPS8), and 28H11(nonopsonic
mouse IgM to PPS8) (Fig. 2b) agglutinated the respective ST,
whereas 5F6 (opsonic mouse IgG1 to PPS3), 31B12 (opsonic
mouse IgG1 to PPS8), and isotype-matched controls did not
(Fig. 2a and b).
To further determine the relationship between the increase in
the frequency of transformation and the expression of the com
two-component regulatory system (TCS), we constructed an
A66.1::comE mutant strain that is unable to induce comX-
FIG 2 PPS-speciﬁc MAbs induce agglutination of
pneumococcus. (a) MAbs A7 (nonopsonic human
[hu]IgMtoPPS3)and1E2(nonopsonicmouse[ms]
IgG1 to PPS3) induce agglutination of ST3 (A66.1);
MAb 5F6 (opsonic mouse IgG1 to PPS3) and human
and mouse isotype-matched controls do not. (b)
54B11 (human IgM to PPS8) and 28H11 (nonop-
sonic mouse IgM to PPS8) induce agglutination of
ST8 (6308); 5G6 (nonopsonic mouse IgM to PC),
31B12 (opsonic mouse IgG1 to PPS8), and human
and mouse isotype-matched controls do not. Wt,
wild type; Ab antibody.
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No transformants were recovered when A66.1::comE was treated
with 1E2 and/or CSP2 (data not shown).
MAb 1E2 induces late pneumococcal competence and alters
geneexpression.Inductionofpneumococcalcompetenceiscon-
trolled by comX, an alternative sigma factor that acts on the pro-
motersitesofdownstreampneumococcalcompetencegenes(17).
ThegenecomXisquiescentinthenoncompetentstatebutrapidly
activated by CSP (17). We determined the effect of 1E2 (nonop-
sonic mouse IgG1 to PPS3) on the induction of comX expression
by quantitative reverse transcription (qRT)-PCR. Two minutes
after the incubation of A66.1 with CSP2 or CSP2 plus 1E2, there
were similar degrees of comX expression (Fig. 3). However, at
8 min after incubation, there was a new second peak of comX
expression with CSP2 plus 1E2 that was not observed with CSP2
alone (Fig. 3) or with a control MAb (data not shown). Samples
collected up to 30 min after CSP2 stimulation did not exhibit the
increaseincomXexpressionthatwasobservedwithCSP2plus1E2
at 8 min after incubation.
MAb 1E2 alters global pneumococcal gene expression. We
used a pneumococcal DNA microarray (Roche NimbleGen, Inc.,
Madison, WI) to determine if 1E2 had an effect on A66.1 gene
expression 2 and 8 min after incubation with CSP2 or CSP2 plus
1E2. These times were chosen based on the times at which in-
creased comX expression was observed with 1E2 plus CSP2
(Fig. 3). Heat maps showing the effects of CSP and 1E2 on global
gene expression of A66.1 are depicted in Figure S3. Tables 1 to 3
(see also Table S2 in the supplemental material) show the genes
that were differentially expressed by 2.5-fold or more by CSP2-
treated versus untreated A66.1 cells (Table S2a), CSP2-treated
versus CSP2-plus-1E2-treated cells at 2 (Table 1) and 8 (Table 2)
min,1E2-treatedversusuntreatedcells(Table3),and/orcontrols.
CSP2 alone markedly upregulated competence-related genes but
downregulatedveryfewgenes(seeTableS2aandb).At2min,the
gene expression of CSP2- and CSP2-plus-1E2-treated cells was
not signiﬁcantly different, although there was more expression of
some competence-related genes in the presence of 1E2 (Table 1).
However, at 8 min, there was a marked increase in DNA
processing-, competence induction-, and fratricide-related genes
in the presence of CSP2 plus 1E2 (Table 2) but very few down-
regulatedgenes(seeTableS2d).Hence,thesecondwaveofCSP2-
plus-1E2-induced comX expression (see Fig. 3) was associated
with increased expression of competence and fratricide genes.
TreatmentofA66.1with1E2alonealsoinducedtheexpressionof
FIG 3 Expression of comX mRNA in the presence of CSP and 1E2. The
expression of comX mRNA was determined by qRT-PCR. Expression was
maximalapproximately2minafterCSP2stimulation.When1E2(nonopsonic
mouse IgG1 to PPS3) and CSP2 were combined, a second peak of comX gene
expressionwasobserved8minafterinitiationofthereaction.Thisexperiment
was repeated multiple times with comparable results.
TABLE 1 Genes differentially expressed by CSP2- and CSP2-plus-1E2 (mouse IgG1 to PPS3)-treated A66.1 cells at 2 min after incubationa
Seq_id Function Fold change
SP_0978080700000908 Competence protein CoiA 4.9
SP_2207080700002076 Competence protein ComF, putative 4.7
SP_1017080700000942 4-Oxalocrotonate tautomerase 3.8
SP_2206080700002075 Ribosomal subunit interface protein 3.6
SP_0395080700000368 Transcriptional regulator, putative 3.4
SP_0047080700000043 Phosphoribosylaminoimidazole synthetase 3.2
SP_0957080700000887 ABC transporter, ATP-binding protein 3.2
SP_2035080700001917 3-Keto-L-gulonate-6-phosphate decarboxylase 3.1
SP_0515080700000482 Heat-inducible transcription repressor 2.9
SP_0021080700000020 Deoxyuridine 5=-triphosphate nucleotidohydrolase 2.9
SP_2208080700002077 Helicase, putative 2.8
SP_2186080700002055 Glycerol kinase 2.8
SP_1113080700001034 DNA-binding protein HU 2.7
SP_1856080700001743 MerR family transcriptional regulator 2.7
SP_1809080700001697 Transcriptional regulator 2.6
SP_1689080700001582 ABC transporter, permease protein 2.6
SP_0516080700000483 Heat shock protein GrpE 2.6
SP_0321080700000304 Phosphotransferase system, IIA component 2.6
SP_2051080700001932 Competence protein CglC 2.6
SP_1898080700001784 -Galactosidase 2.6
SP_0090080700000084 ABC transporter, permease protein 2.6
SP_2031080700001913 Putative L-ascorbate 6-phosphate lactonase 2.5
SP_2036080700001918 Phosphotransferase system, IIA component 2.5
SP_1813080700001701 N-(5=-Phosphoribosyl)anthranilate isomerase 2.5
a Genes that exhibited a 2.5-fold increase are shown. For the hypothetical genes not included here, see Table S3 in the supplemental material.
Yano et al.
4
® mbio.asm.org September/October 2011 Volume 2 Issue 5 e00176-11bacteriocingenes,includingblpN,blpO,blpM,blpI,andblpC(Ta-
ble 2), which was not observed with a control (PPS8-speciﬁc)
MAb or with CSP2 alone (see Table S2a, b, and f).
MAb1E2increasesCSP2-mediatedagglutinationandfratri-
cide. The effect of CSP2 with or without 1E2 (nonopsonic mouse
IgG1 to PPS3) on A66.1 agglutination and fratricide was investi-
gatedbyﬂowcytometryandﬂuorescencemicroscopy.A66.1cells
were stained with SYTO-9 (to detect all bacterial cells) and pro-
pidium iodide (PI; to detect dead cells), and cell viability was
examined by ﬂow cytometry (Fig. 4a to f). Incubation of A66.1
with CSP2 alone resulted in 21.7% death (Fig. 4a), while incu-
bation with CSP2 plus 1E2 resulted in 42% death. Although
this nearly 2-fold increase did not reach statistical signiﬁcance
(P  0.11, Student’s t test, Fig. 4c), an increase was not ob-
served with CSP2 plus a control MAb, CSP1, or 1E2 alone. Less
than 1% killing was observed after the incubation of A66.1::
comEwitheitherCSP2orCSP2plus1E2(mouseIgG1toPPS3)
(Fig. S4). The ability of 1E2 to increase CSP2-mediated agglu-
TABLE 2 Genes differentially expressed by CSP2- and CSP2-plus-1E2 (mouse IgG1 to PPS3)-treated cells 8 min after incubationa
Seq_id Function Fold change
SP_1266080700001180 DNA processing protein DprA, putative 64.1
SP_2207080700002076 Competence protein ComF, putative 49.3
SP_0955080700000885 Competence protein CelB 46.8
SP_2208080700002077 Helicase, putative 39.7
SP_0954080700000884 Competence protein CelA 38.4
SP_0957080700000887 ABC transporter, ATP-binding protein 31.0
SP_1808080700001696 Type IV prepilin peptidase, putative 29.7
SP_2201080700002070 Choline-binding protein D 29.0
SP_1908080700001793 Single-stranded DNA-binding protein 27.7
SP_2053080700001934 Competence protein CglA 26.4
SP_2050080700001931 Competence protein CglD 26.4
SP_0042080700000038 Competence factor transporting ATP-binding/permease protein ComA 24.7
SP_2052080700001933 Competence protein CglB 21.5
SP_0978080700000908 Competence protein CoiA 21.4
SP_2236080700002101 Putative sensor histidine kinase ComD 17.5
SP_1988080700001872 Immunity protein, putative 17.0
SP_1941080700001825 Competence damage-inducible protein A 16.6
SP_1717080700001609 ABC transporter, ATP-binding protein 16.1
SP_0544080700000510 Immunity protein BlpX 15.1
SP_0014080700000014 Transcriptional regulator ComX1 14.7
SP_1088080700001010 DNA repair protein RadC 14.5
SP_0043080700000039 Competence factor transport protein ComB 13.6
SP_2235080700002100 Response regulator ComE 12.9
SP_0030080700000027 Competence-induced protein Ccs16 9.4
SP_1987080700001871 ABC transporter, ATP-binding protein 9.0
SP_1809080700001697 Transcriptional regulator 8.4
SP_0529080700000496 BlpC ABC transporter 8.0
SP_0545080700000511 Immunity protein BlpY 7.4
SP_1110080700001031 Bifunctional riboﬂavin kinase/ﬂavin mononucleotide adenylyltransferase 6.3
SP_2051080700001932 Competence protein CglC 5.6
SP_0524080700000491 BlpT protein, fusion 5.1
SP_0021080700000020 Deoxyuridine 5=-triphosphate nucleotidohydrolase 5.1
SP_0528080700000495 Peptide pheromone BlpC 4.7
SP_1714080700001606 GntR family transcriptional regulator 4.5
SP_1089080700001011 Glutamine amidotransferase, class I 4.3
SP_1812080700001700 Tryptophan synthase subunit beta 3.8
SP_0942080700000874 IS1381 transposase protein A 3.7
SP_1894080700001780 Sucrose phosphorylase 3.7
SP_2206080700002075 Ribosomal subunit interface protein 3.5
SP_1310080700001221 IS1381 transposase protein A 3.1
SP_2239080700002104 Serine protease 3.1
SP_1939080700001823 MATE efﬂux family protein DinF 3.0
SP_1940080700001824 Recombinase A 3.0
SP_1549080700001446 Peptide deformylase 3.0
SP_1811080700001699 Tryptophan synthase subunit alpha 3.0
SP_1072080700000995 DNA primase 3.0
SP_0048080700000044 Phosphoribosylglycinamide formyltransferase 2.8
SP_2240080700002105 spspoJ protein 2.7
SP_0050080700000046 Bifunctional phosphoribosylaminoimidazolecarboxamide formyltransferase/IMP cyclohydrolase 2.7
SP_0647080700000602 Phosphotransferase system, IIC component, putative 2.7
SP_0062080700000058 Phosphotransferase system, IIC component 2.7
SP_0049080700000045 VanZ protein, putative 2.7
a Genes that exhibited a 2.5-fold increase are shown. For the hypothetical genes not included here, see Table S3 in the supplemental material.
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ing and ﬂuorescence microscopy (Fig. 4g to l).
MAb 1E2 increases CSP2-mediated PPS secretion. The
amount of PPS3 secreted by A66.1 cells after incubation with
MAbs was quantiﬁed by enzyme-linked immunosorbent assay
(ELISA). There was no signiﬁcant difference in the amount of
PPS3 secreted by MAb-treated cells prior to the addition of CSP2
in any of the groups tested in this study. The addition of CSP2 to
1E2 (nonopsonic mouse IgG1 to PPS3)-treated A66.1 cells re-
sulted in a statistically signiﬁcant increase in PPS3 secretion com-
pared to that of CSP2-treated A66.1 cells treated with CSP2 alone
or with control MAb 31B12 (opsonic mouse IgG1 to PPS8; P 
0.05 by one-way analysis of variance [ANOVA] and P  0.05 by
Tukey’s multiple-comparison test comparing CSP2 to 1E2 plus
CSP2) (Fig. 5).
DISCUSSION
In this article, we report that certain PPS-speciﬁc MAbs that pro-
tectagainstST3andST8pneumoniaand/orsepsisinmice(8–10)
increase the transformation frequency of the homologous ST in
the presence of CSP. For ST3 (A66.1), this phenomenon was me-
diated by protective, nonopsonic MAbs to PPS3, including a hu-
man IgM (A7) and a mouse IgG1 (1E2) that induced the aggluti-
nation of ST3, but not a protective, opsonic mouse IgG1 (5F6)
that did not induce agglutination. Notably, 1E2-mediated en-
hancement of pneumococcal transformation frequency was even
greater for an MDR ST3 clinical strain (LI-736). Further work is
required to identify an explanation for this phenomenon; how-
ever,asthefoldincreasesin1E2-mediatedenhancementofA66.1
and LI-736 transformation were similar, our result could reﬂect
thetransformabilityandplasticityofdrug-resistantpneumococci
(2). For ST8 (6308), an increase in transformation frequency was
mediated by two protective IgM MAbs to PPS8 (54B11 and
28H11) that induced agglutination of ST8 but not by a protective
opsonicIgG1(31B12)thatdidnotinduceagglutination.Neithera
nonprotective MAb to PC (5G6) nor a human IgM to another
capsular polysaccharide (G19) increased the transformation fre-
quency of or agglutinated ST8 or ST3, respectively. Hence, our
data reveal a relationship between MAb-induced agglutination
and the bacterial transformation frequency.
The PPS3-speciﬁc MAb 1E2 is highly protective and induces
bacterial clearance in mice, despite being unable to induce op-
sonophagocytic killing in vitro (9). Our data show that 1E2 (non-
opsonic mouse IgG1 to PPS3) promotes ST3 agglutination. To
investigate the effect of such binding on pneumococcal biology,
weperformedgeneexpressionproﬁlingwithaST3strain(A66.1).
These experiments revealed two main ﬁndings. First, incubation
ofA66.1withCSP2plus1E2inducedanew,secondwaveofcom-
petence induction 8 min after incubation manifested by an in-
creaseincomXexpressionthatwasnotobservedwithCSP2alone.
This second wave of comX expression was associated with a
marked increase in the expression of pneumococcal competence-
related and bacteriocin, including immunity, genes such as blpX
and blpY. The mechanism by which this second wave of comX
expression was induced is unknown. However, given that 1E2
induces bacterial agglutination, this state could enhance or pro-
long cell-cell communication, thereby triggering quorum sensing
andfratricide(12,18).Wefoundthattheadditionof1E2toCSP2
resultedinanalmost2-foldincreaseinfratricideandcelldeathby
ﬂow cytometry and ﬂuorescence microscopy, respectively. Al-
thoughthisincreasewasnotstatisticallysigniﬁcant,wenotethata
change of this magnitude could be biologically signiﬁcant.
The second main ﬁnding in our microarray experiments was
that 1E2 (mouse IgG1 to PPS3) alone increased the expression of
blp TCS bacteriocin genes, irrespective of the presence of CSP2.
Hence, 1E2 (mouse IgG1 to PPS3) had a distinct effect on A66.1
that was independent of CSP2. Expression of blp family genes
occurs during stationary-phase growth (19). Certain bacteriocins
have been implicated in driving interspecies competition among
pneumococci (20). Hence, although the direct effect of 1E2
(mouse IgG1 to PPS3) on bacteriocins and its possible effect on
pneumococcal fratricide, ﬁtness, and biology require further
study, our data suggest that in the presence of CSP2, 1E2 (mouse
IgG1 to PPS3)-induced changes in A66.1 gene expression could
TABLE 3 Genes differentially expressed by 1E2 (mouse IgG1 to PPS3)-treated and untreated A66.1 bacterial cells grown to an OD405 of 0.032a
Seq_id Function Fold change
SP_0540080700000506 BlpN protein 10.2
SP_0541080700000507 Bacteriocin BlpO 5.6
SP_1330080700001238 N-Acetylmannosamine-6-phosphate 2-epimerase 4.8
SP_0464080700000433 Cell wall surface anchor family protein 4.6
SP_0539080700000505 Bacteriocin BlpM 3.8
SP_0468080700000437 Sortase, putative 3.5
SP_0528080700000495 Peptide pheromone BlpC 3.3
SP_1336080700001244 Type II DNA modiﬁcation methyltransferase Spn5252IP 3.2
SP_0053080700000049 Phosphoribosylaminoimidazole carboxylase catalytic subunit 3.2
SP_2092080700001969 UTP-glucose-1-phosphate uridylyltransferase 3.1
SP_0074080700000070 Acetyltransferase 2.9
SP_0978080700000908 Competence protein CoiA 2.8
SP_0046080700000042 Amidophosphoribosyltransferase 2.7
SP_0044080700000040 Phosphoribosylaminoimidazolesuccinocarboxamide synthase 2.7
SP_0531080700000497 Bacteriocin BlpI 2.7
SP_1343080700001251 Prolyl oligopeptidase family protein 2.7
SP_0048080700000044 Phosphoribosylglycinamide formyltransferase 2.7
SP_0047080700000043 Phosphoribosylaminoimidazole synthetase 2.7
SP_0466080700000435 Sortase, putative 2.6
SP_2142080700002017 ROK family protein 2.6
a Genes that exhibited a 2.5-fold increase are shown. For the hypothetical genes not included here, see Table S3 in the supplemental material.
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® mbio.asm.org September/October 2011 Volume 2 Issue 5 e00176-11translate into reduced bacterial viability via fratricide of noncom-
petent cells, while increasing competence for genetic exchange.
Antibioticshavebeenshowntoexertdirecteffectsonpneumo-
coccal quorum sensing and gene expression (21, 22). Other
groupshaveshownthatwhilepenicillinupregulatestheciaR-ciaH
TCS and reduces com TCS (22), mitomycin C, aminoglycosides,
and ﬂuoroquinolones increase com TCS (21) expression. In con-
trast to the foregoing effect of penicillin, 1E2 (mouse IgG1 to
PPS3) plus CSP2 increased transformation frequency and
competence-related gene expression of A66.1 and 1E2 alone in-
creased fratricide-related gene expression. These ﬁndings estab-
lish that PPS-speciﬁc antibody can affect pneumococcal biology,
revealing an effect that is different from that of penicillin. Thus,
ourdatasuggestthatpenicillinandantibodycouldexertdifferent
effects on the host response. Consistent with this idea, penicillin
and the protective, nonopsonic MAb A7 (human IgM to PPS3)
affected the splenic cytokine response differently, even though
eachmediatedbacterialclearanceinamousemodel(8).Theabil-
ity of a MAb to affect microbial biology has been demonstrated
previouslyforaMAbtothecapsularpolysaccharideofCryptococ-
cusneoformans,whichalteredfungalgeneexpressionandantifun-
gal susceptibility (23).
Moreworkisrequiredtounravelthemechanismbywhich1E2
binding to the A66.1 capsule affects gene expression. Given that
the blp locus is a bacterial TCS (24), one possibility is that 1E2
(nonopsonic mouse IgG1 to PPS3) binding evokes signal trans-
FIG 4 (a to f) Quantiﬁcation of pneumococcal fratricide by ﬂow cytometry. Pneumococcal viability studies were performed by live-dead staining as described
in Materials and Methods. Dead ST3 (A66.1) cells appear in the upper right quadrant as doubly positive for green ﬂuorescence (SYTO-9) and red ﬂuorescence
(PI). Live cells appear in the lower right quadrant as singly positive for SYTO-9. Bacterial killing by CSP2 (a), 1E2 (nonopsonic mouse IgG1 to PPS3) (b), CSP2
plus 1E2 (c), CSP1 (control CSP) (d), 31B12 (opsonic mouse IgG1 to PPS8) (e), and CSP1 plus 31B12 (f) is shown. (g to l) Immunoﬂuorescence imaging of
pneumococci treated with CSP2 and 1E2. Live bacteria ﬂuoresce green, and dead bacteria ﬂuoresce red. Bacterial killing by CSP2 (g), 1E2 (nonopsonic mouse
IgG1 to PPS3) (h), CSP2 plus 1E2 (I), CSP1 (j), 31B12 (opsonic mouse IgG1 to PPS8) (k), and CSP1 plus 31B12 (l) is shown.
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® mbio.asm.org 7duction pathways that occur under conditions of stress. A mech-
anism by which this could occur is via 1E2-induced changes to
capsular morphology and/or induction of capsular shedding by
CSP2-treated cells. The latter was observed in this study. In other
words,1E2couldenhancequorumsensingbyenhancingtheabil-
ity of CSP2 to bind COMD, the CSP-binding protein on the cell
membrane,bymakingitmoreaccessible.Thereisaprecedentfor
this phenomenon; capsular binding of MAbs to cryptococcal
polysaccharide has been shown to expose otherwise cryptic or
hidden fungal determinants (25, 26).
TheﬁndingsinthisstudyraisethepossibilitythatcertainPPS-
speciﬁcMAbscouldreducebacterialviabilityinvivobyenhancing
fratricide. We realize that the idea that an antibody to a Gram-
positiveorganismcouldhaveadirecteffectonbacterialviabilityis
unconventional. Nonetheless, new mechanisms of antibody ac-
tion, including direct antimicrobial effects (27), suggest that this
idea warrants further consideration. Our data show that PPS-
speciﬁc MAbs can increase the frequency of pneumococcal trans-
formation and that such MAbs induce bacterial agglutination,
suggestingthatPPS-speciﬁcantibodiesthatbringpneumococciin
close proximity to one another could trigger and/or enhance
quorum-sensing-related phenomena such as competence induc-
tion and fratricide. Fratricide could translate into a bacterial bur-
den reduction. Another way in which PPS-speciﬁc MAbs that af-
fect quorum sensing could inﬂuence bacterial biology in the host
is via immunomodulation. Immunomodulation has been associ-
ated with the efﬁcacy of nonopsonic MAbs to PPS3 (8, 9, 11).
Alongtheselines,abacterialquorum-sensingpeptidewasrecently
shown to modulate the inﬂammatory response to Aeromonas in
mice (14), and CSP treatment prolonged the survival of mice in a
pneumococcal infection model (13). On the other hand, our data
raise questions regarding the inﬂuence of PPS-speciﬁc antibody
on ST replacement and antibiotic resistance. Do certain antibod-
ies promote these phenomena by increasing pneumococcal com-
petence for transformation and genetic exchange? More work is
neededtoanswerthisquestionandunderstandthemyriadeffects
that antibody-induced and/or enhanced quorum sensing have on
pneumococcal biology and host defense. Nonetheless, our ﬁnd-
ings reveal a novel, heretofore unknown, mechanism by which
certain PPS-speciﬁc antibodies interact with pneumococci and
suggestnewavenuesofexplorationtoenhanceourunderstanding
of host-pneumococcus interaction and antibody-mediated im-
munity to pneumococci.
MATERIALS AND METHODS
Strains and growth conditions. The pneumococcal strains used in this
study were A66.1 (28) (originally provided by D. Briles, University of
Alabama),LI-736(15)(providedNurithPorat,Ben-GurionUniversityof
the Negev), 6308 (ATCC, Manassas, VA), and A66.1::comE (constructed
for this study). All strains were propagated in Todd-Hewitt broth (Difco
Laboratories, Detroit, MI) supplemented with 0.5% yeast extract (Difco
Laboratories, Detroit, MI) in liquid phase or in solid phase on agar plates
containing 5% sheep blood (BD, Franklin Lakes, NJ), unless otherwise
indicated. Recombinant strains were propagated in medium containing
200g/mlkanamycin.Thestrainsweregrownin5%CO2at37°C(unless
otherwise indicated) and frozen in Todd-Hewitt broth with 0.5% yeast
extract medium in 10% glycerol.
MAbs. The MAbs used in this study are listed in Table 4.
Opsonophagocytosis killing assays. Opsonophagocytosis killing as-
says were performed with PPS-speciﬁc MAbs 31B12 and 28H11 to evalu-
atetheirabilitiestoenhancethephagocytosisandkillingofbacteriabythe
murine macrophage-like cell line J774.16 as previously described (9).
MAb concentrations of 0.1 g/ml, 1 g/ml, and 10 g/ml were added to
103CFUofST8strain6308(ATCC),andthevolumewasadjustedto30l
with Veronal buffer (Lonza, Walkersville, MD). After incubation for
15 min at 37°C, 10% (by volume) mouse serum was added as a comple-
ment source (Sigma-Aldrich, St. Louis, MO) and then 4  105 J774.16
cells/well were added to achieve an effector-to-target cell (E/T) ratio of
400:1. This E/T ratio has been used previously in opsonophagocytosis
killing assays with ST8 (29). After incubation for 45 min at 37°C, the
mixture was diluted with Veronal buffer (Lonza, Walkersville, MD) and
plated onto blood agar plates (BD, Franklin Lakes, NJ) in duplicate. The
plates were incubated overnight at 37°C with 5% CO2, and colonies were
counted. The number of colonies for each condition was determined as a
percentage of the number of colonies with no MAb, e.g., for bacteria and
MAb, for bacteria only; for bacteria, MAb, and J774.1 cells, for bacteria
and J774.1 cells, etc.
Competence induction and determination of pneumococcal trans-
formation frequencies. Pneumococcal cultures were initiated by growth
of a 1:100 dilution of an overnight culture to early log-phase: an optical
density at 550 nm (OD550) of approximately 0.02 (measured with a
Thermo Scientiﬁc Biomate 3) with the culture pH adjusted to 7.8 with
0.1 M NaOH. Subsequently, 1-ml aliquots of bacteria were made and
10 g of antibody was added, except where noted otherwise. Cells were
thengrowntoanOD550ofapproximately0.032.CSP2(100ng/ml)forthe
ST3 strain, CSP1 (100 ng/ml) for the ST8 strain (AnaSpec), and 100 ng of
FIG 5 Quantiﬁcation of secreted pneumococcal capsules treated with CSP2
and 1E2.The amount of PPS3 secreted by A66.1 cells left unstimulated or
stimulated with CSP2, as indicated, is shown on the y axis for the MAbs indi-
catedonthexaxis.TreatmentofCSP2-stimulatedcellswith1E2(mouseIgG1
to PPS3), but not the other MAbs, resulted in increased PPS3 secretion, in
contrast to CSP2 and control MAb (*, P  0.05 by one-way ANOVA and P 
0.05 by Tukey’s multiple-comparison test).
TABLE 4 MAbs used in this study
MAb Speciﬁcitya Species/isotype Efﬁcacy in mice Reference(s)
1E2 ST3 Mouse IgG1 Protective 9
A7 ST3 Human IgM Protective 8, 33
5F6 ST3 Mouse IgG1 Protective 9
31B12 ST8 Mouse IgG1 Protective 16
54B11 ST8 Human IgM Protectivec 11
28H11 ST8 Mouse IgM Protective 16
G19 GXMb Mouse IgM NTd 34
5G6 PC Mouse IgM Nonprotective 16
a ST of capsular polysaccharide recognized by MAb.
b GXM, C. neoformans capsular polysaccharide glucuronoxylomannan.
c Unpublished.
d NT, not tested against pneumococci.
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plemented with 0.1 mM CaCl2, and then the cultures were incubated for
30 min at 30°C and additionally for 30 min at 37°C. After incubation, the
cultures were serially diluted and plated on kanamycin (200 g/ml)-con-
taining plates. Positive colonies were identiﬁed by drug resistance
(growth) the next day. The transformation frequency was calculated as a
percentage of the input number of CFU by dividing the number of CFU
afterthereactionbythenumberofCFUatthetimecompetenceinduction
was started.
Fluorescence microscopy to determine agglutination. A suspension
of approximately 106 CFU of bacteria was labeled with Oregon Green
488-carboxylic acid diacetate succinimidyl ester mixed isomers (600:1;
Invitrogen,Carlsbad,CA)overnightat4°C.Onthefollowingday,labeled
bacteria were incubated with the PPS3-speciﬁc, the PPS8-speciﬁc, or the
PC-reactive MAb in tryptic soy broth for1ha t37°C. After three washes
(centrifugation at 8,000  g for 20 min), cells were resuspended in 5 to
10 l of ProLong gold antifade reagent (Invitrogen, Carlsbad, CA). All
ﬂuorescent images were taken on an Axio Imager microscope (Carl Zeiss
MicroImaging)atﬁnalmagniﬁcationsof630and1,000.Photomicro-
graphswerecapturedusinganAxioCamMRmcamera(CarlZeissMicro-
Imaging).CapturedphotomicrographswereadjustedbyAxiovision4.7.2
(CarlZeissMicroImaging)forcontrast,balance,andcolorsaturation.All
resizing of images was done by taking care to keep dimensions and size
ratios intact.
Construction of A66.1::comE strain. Mini prep (Qiagen), Clone Jet
PCRcloning(Fermentas),andRapidDNAligation(Fermentas)kitswere
usedforstrainconstructionaccordingtothemanufacturers’instructions.
ToconstructtheA66.1::comEstrain,genomicDNAofCPM17containing
a kanamycin resistance cassette in the ComE-encoding region (provided
byD.Morrison,UniversityofIllinois,Chicago)wasampliﬁedwithprim-
ersComEup5(CTCATAAAGTTCTGGAGAAAGAGATTGCTTTGA
AGCA)andComEdown3(GGCGCGCCAATAACATCTTCTAAAATT
AAAACTTTCAT)andthenclonedintovectorpJET1.3(seeFig.S2inthe
supplemental material). The vector containing the comE mutant gene
(kanamycin cassette) was subsequently transformed into wild-type strain
A66.1 as described above.
qRT-PCR. Aliquots from cultures in which competence was induced
asdescribedaboveweretakenevery30sfor20minafterCSPstimulation,
immediatelyspundownat4°Cfor15minat17,000g,andresuspended
in RNAprotect Bacteria Reagent (Invitrogen), and pellets were stored at
20°C until use. To prepare cells for PCR, glass beads were used to me-
chanically disrupt the cells and mRNA was isolated using the MICROB-
ExpressbacterialmRNAenrichmentkit(Ambion)accordingtotheman-
ufacturer’sinstructions.IsolatedmRNAwasreversetranscribedtocDNA
with a Maxima Universal ﬁrst-strand cDNA synthesis kit (Fermentas),
and qRT-PCR was performed using Power SYBR Green PCR Master Mix
(Applied Biosystems) according to the manufacturer’s instructions. For
the primers used in this experiment, see Table S1 in the supplemental
material. The 16S rRNA housekeeping gene was used as an internal con-
trol.
Flow cytometry. Upon competence induction as described above,
bacteria were pipetted, vortexed, and sonicated to disrupt clump forma-
tion. Approximately 106 bacteria were stained with a 1.5:1 ratio of green
ﬂuorescent SYTO-9, which stains all cells with intact membranes and red
ﬂuorescent PI, which penetrates only bacteria with damaged cell mem-
branes (LIVE/DEAD BacLight bacterial viability kit; Invitrogen). Cells
were incubated at 4°C for 20 min, centrifuged, washed, and resuspended
in 2% paraformaldehyde. Data were acquired on a FACSCanto II (BD)
ﬂow cytometer interfaced to BD FACSDiva software with the forward
scatterthresholdadjustedto300andsingle-colorcontrolsforcompensa-
tion.Positivecontrolswithvariousconcentrationsofliveanddead(heat-
killed) bacteria were included, as well as single-color controls for each
sampletoensurepropergating.Asmanyeventswereacquiredaspossible,
with a minimum of 100,000 events per sample, each of which was run in
duplicate. All analyses were performed using FlowJo software version 9.2
(Treestar). Pneumococcal viability was conﬁrmed by ﬂuorescence mi-
croscopy to evaluate live (green) and dead (red) bacteria.
Microarray experiments. Microarrays were prepared with the S.
pneumoniaeTIGR4385K4-plexarray(RocheNimbleGen).Thismicroar-
rayhasbeenusedextensivelyforstudiesofpneumococcalgeneexpression
(31,32).Microarrayanalysiswasperformedforthefollowingconditions:
(i)untreatedcells;(ii)CSP2aloneat2min,(iii)CSP2aloneat8min,(iv)
CSP plus 1E2 (nonopsonic mouse IgG1 to PPS3) at 2 min, (v) CSP2 plus
1E2 at 8 min, (vi) 1E2 alone, and (vii) 31B12 (opsonic mouse IgG1 to
PPS8). All mRNAs were prepared as described above. Subsequently, they
were ampliﬁed using the MICROBExpress bacterial mRNA enrichment
kit(Ambion).Allofthesampleswereduplicatedbyseparatepreparation.
Labeling, hybridization, scanning, and data analysis were done at Roche
NimbleGen, Inc. (Madison, WI). This array detects 2,094 S. pneumoniae
open reading frames. Prepared slides were hybridized with Cy-3-labeled
samplesandscannedwithaNimbleGenMS200microarrayscanner.Data
analysis was performed using raw ﬂuorescence intensity values with mi-
croarray suite version 5.0. Gene functions were annotated from the Na-
tional Center for Biotechnology Information (NCBI) database, and fur-
ther data analysis was done with ArrayStar (DNASTAR, Inc., Madison,
WI).
Quantiﬁcation of capsular polysaccharide secretion by cultured
cells.Pneumococcalcultureswereinitiatedbygrowinga1:100dilutionof
an overnight culture to early log phase, i.e., an OD550 of approximately
0.02, under the culture conditions described above. Subsequently, 1.0-ml
aliquots of bacteria were prepared and 10 g of MAb was added to the
cells, which were then grown to an OD550 of approximately 0.032. CSP2
(100ng/ml)wasthenadded,andthereactionmixtureswereincubatedfor
30 min at 30°C and then for 30 min at 37°C. Pre- and post-CSP stimula-
tionsampleswerecollectedimmediatelypriortotheadditionofCSP2and
30 min after incubation at 37°C, respectively. The supernatants were col-
lected by centrifugation, heat killed at 65°C for 15 min, and stored at 4°C
until use. Secreted PPS was harvested by centrifugation for 12 min at
14,000  g, and culture supernatant ﬂuids were ﬁltered and saved. PPS
was quantiﬁed by capture ELISA as follows. Wells of polystyrene ELISA
plates (Corning Glass Works, Corning, NY) were coated with 1.0 g/ml
PPS3-speciﬁc MAb A7 (human IgM) (8, 11, 33) or PPS8-speciﬁc MAb
28H11(mouseIgM)(16)andincubatedwithseriallydilutedsupernatants
from the cell cultures. After being washed, the plates were incubated at
37°Cfor1hwithsecondaryMAbstoPPS3(1E2,mouseIgG1toPPS3)and
PPS8 (31B12, mouse IgG1 to PPS8). Alkaline phosphatase-conjugated
goatanti-humansecondaryantibody(SouthernBiotechnology,Birming-
ham, AL) was then added. After the plates were washed, bound antibody
was detected by developing the plates with p-nitrophenylphosphate sub-
strate (Sigma-Aldrich, St. Louis, MO). A Sunrise absorbance reader
(Tecan, Durham, NC) was used to record ODs. Relative quantities of
capsular polysaccharides were determined by normalizing the OD values
obtained to standard curves that were generated by quantiﬁed capsular
polysaccharide (ATCC, Manassas, VA).
Statisticalevaluation.Differencesinthetransformationfrequencyof
and PPS secretion by A66.1 cells were analyzed using Student’s t test or
Turkey’smultiple-comparisontestafterascertainingthenormalitydistri-
butionofthedatabyone-wayANOVA.Atwo-tailedPvalueof0.05was
consideredsigniﬁcant.AllstatisticalanalyseswereperformedusingPrism
(version 5.02 for Windows; GraphPad Software, San Diego, CA).
Microarraydataaccessionnumber.TheNCBIGeneExpressionOm-
nibus accession number for the microarray data in this report is
GSE27258.
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